Search results for "Topi"

showing 10 items of 3172 documents

Activin and inhibin A in predicting outcome of pregnancies of unknown location after ART

2018

Abstract The aim was to investigate the predictive value of a single serum determination of activin A and inhibin A for classifying pregnancies of unknown location (PUL) after IVF cycles in both own fresh and donated oocytes. A case–control study conducted in a University-affiliated IVF center. Pregnancy outcomes after own fresh oocytes included 12 failing PUL, 12 ectopic pregnancies (EP) and a control group of 24 singleton intrauterine pregnancies (IUP). The same scheme was followed for the oocyte donation recipients. Inhibin A, activin A, β-hCG and Progesterone (P) were determined. In the own fresh oocytes IVF, the AUC for predicting EP vs. f failing PUL were: Activin A: 0.458 and Inhibin…

0301 basic medicineendocrine systemPregnancyInhibin a030219 obstetrics & reproductive medicineEctopic pregnancybusiness.industryActivin and inhibinmedicine.diseasefemale genital diseases and pregnancy complicationsActivin aAndrology03 medical and health sciences030104 developmental biology0302 clinical medicineInduced ovulationOocyte donationMedicineBiomarker (medicine)businessreproductive and urinary physiologyhormones hormone substitutes and hormone antagonistsMedicina Reproductiva y Embriología Clínica
researchProduct

The impact of galactooligosaccharides on the bioaccessibility of sterols in a plant sterol-enriched beverage: adaptation of the harmonized INFOGEST d…

2018

The effect of the addition of galactooligosaccharides (GOS) on sterol bioaccessibility in three plant sterol (PS)-enriched milk-based fruit beverages (without GOS addition (MfB) and with 2.5 g (MfB-G2) and 5.0 g (MfB-G5) GOS per 250 mL) was evaluated after micellar gastrointestinal digestion. Cholesterol bioaccessibility was very similar among beverages, though a slight significant increase (from 80% to 85%) was observed by the addition of 5.0 g GOS. The addition of GOS did not affect total PS bioaccessibility (≈37%). Based on the results obtained after micellar digestion, it has been demonstrated that these beverages could be a suitable food matrix for simultaneous enrichment with PS and G…

0301 basic medicinefood.ingredientFood technologyGuidelines as TopicIn Vitro TechniquesMicelleModels BiologicalMatrix (chemical analysis)Bile Acids and SaltsCholesterol Dietary03 medical and health scienceschemistry.chemical_compoundfoodGastrointestinal AgentsAnimalsHumansFood scienceMicellesGlycoproteinsFoods SpecializedGastrointestinal agent030109 nutrition & dieteticsbusiness.industryChemistryCholesterolFood additivePhytosterolsGeneral MedicineLipid DropletsInflammatory Bowel DiseasesSterolFruit and Vegetable JuicesCardiovascular DiseasesResearch DesignFood Technologylipids (amino acids peptides and proteins)DigestionFood AdditivesDairy ProductsGlycolipidsDigestionbusinessNutritive ValueTrisaccharidesFood ScienceFoodfunction
researchProduct

New Highlights of Resveratrol: A Review of Properties against Ocular Diseases

2021

Eye diseases are currently a major public health concern due to the growing number of cases resulting from both an aging of populations and exogenous factors linked to our lifestyles. Thus, many treatments including surgical pharmacological approaches have emerged, and special attention has been paid to prevention, where diet plays a preponderant role. Recently, potential antioxidants such as resveratrol have received much attention as potential tools against various ocular diseases. In this review, we focus on the mechanisms of resveratrol against ocular diseases, in particular age-related macular degeneration, glaucoma, cataract, diabetic retinopathy, and vitreoretinopathy. We analyze, in…

0301 basic medicinegenetic structuresEye DiseasesReviewDiseaseresveratrolAMDResveratrolBioinformaticsAntioxidantsEpigenesis Geneticlcsh:Chemistryangiogenesischemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineSirtuin 1Gene Regulatory Networkslcsh:QH301-705.5Spectroscopy3309.20 Propiedades de Los AlimentosClinical Trials as TopicGeneral MedicineDiabetic retinopathyComputer Science Applicationsdiabetic retinopathycataract3201.09 OftalmologíanutraceuticalCatalysisInorganic Chemistry03 medical and health sciences2302 BioquímicamedicineHumansPhysical and Theoretical ChemistryMolecular BiologypolyphenolsMolecular signalingbusiness.industryocular diseasesOrganic ChemistryeyesMacular degenerationmedicine.diseaseeye diseasesClinical trial030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Gene Expression Regulationchemistry030221 ophthalmology & optometryReactive Oxygen SpeciesbusinessInternational Journal of Molecular Sciences
researchProduct

Bordeaux 2018: Wine, Cheese, and γδ T Cells

2019

The first ‘International γδ T cell conference’ took place in Denver, CO (USA) in 2004. Since then, a new meeting is held every two years. During each conference, all participants voted to choose between candidate bids for where to hold the next conference. At the conference held in London in 2016, a majority opted for the bid from a team proposing the 2018 event be held in Bordeaux, France – which is where we therefore gathered on 7-10th of June 2018. The meeting was an undisputed success and it gave us the opportunity to take stock of the increasing basic knowledge about γδ T cells as well as the rapidly expanding interest and activities developing using γδ T cells towards clinical applica…

0301 basic medicinelcsh:Immunologic diseases. AllergyOpinionrecent advancesT cellImmunologyReceptors Lymphocyte HomingLibrary scienceInfectionsLymphocyte Activation03 medical and health sciences0302 clinical medicineBasic knowledgeongoing researchT-Lymphocyte SubsetsPolitical scienceNeoplasmsmedicineImmunology and AllergyAnimalsHumansgamma delta T cellsInflammationButyrophilinsReceptors Antigen T-Cell gamma-deltaCongresses as Topicfutures perspectives030104 developmental biologymedicine.anatomical_structureconference reportImmunotherapylcsh:RC581-607030215 immunologyFrontiers in Immunology
researchProduct

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells

2018

CD38 is overexpressed by multiple myeloma cells and has emerged as a target for therapeutic antibodies. Nanobodies are soluble single domain antibody fragments derived from the VHH variable domain of heavy chain antibodies naturally occurring in camelids. We previously identified distinct llama nanobodies that recognize three non-overlapping epitopes of the extracellular domain of CD38. Here, we fused these VHH domains to the hinge, CH2, and CH3 domains of human IgG1, yielding highly soluble chimeric llama/human heavy chain antibodies (hcAbs). We analyzed the capacity of these hcAbs to mediate complement-dependent cytotoxicity (CDC) to CD38-expressing human multiple myeloma and Burkitt lymp…

0301 basic medicinelcsh:Immunologic diseases. AllergyRecombinant Fusion ProteinsImmunologyAntineoplastic AgentsEpitope03 medical and health sciencesbiparatopic antibodiesAntigens Neoplasmhemic and lymphatic diseasesCell Line TumorAntibodies BispecificImmunology and AllergyAnimalsHumansCytotoxicitycomplement-dependent cytotoxicityOriginal ResearchHeavy-chain antibodybiologyheavy chain antibodyantibody engineeringChemistryAntibody-Dependent Cell CytotoxicityDaratumumabAntibodies MonoclonalComplement System ProteinsSingle-Domain AntibodiesADP-ribosyl Cyclase 1Complement-dependent cytotoxicityCell biologymultiple myelomananobody030104 developmental biologySingle-domain antibodyCell culturebiology.proteinEpitopes B-LymphocyteImmunotherapyAntibodylcsh:RC581-607Immunoglobulin Heavy ChainsCamelids New WorldCD38Frontiers in Immunology
researchProduct

Treatment of multiple myeloma-related bone disease

2021

In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease. After assessing the available literature and grading recommendations using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) method, experts from the working group recommend zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma, with or without multiple myeloma-related bone disease. Once patients achieve a very good partial response or better, after receiving monthly zoledronic acid for at least 12 months, the treating…

0301 basic medicinemedicine.medical_specialtyBone Density Conservation AgentBone disease03 medical and health sciences0302 clinical medicineSpinal cord compressionmedicineHumansMultiple myelomaBone Density Conservation Agentsbusiness.industrymedicine.diseaseSurgeryDiscontinuationTransplantationBone Density Conservation Agents030104 developmental biologyZoledronic acidDenosumabOncology030220 oncology & carcinogenesisPractice Guidelines as TopicBone DiseasesbusinessBone DiseaseMultiple Myelomamedicine.drugHumanThe Lancet Oncology
researchProduct

Alzheimer's disease: Only prevention makes sense

2018

Alzheimer's disease therapeutics is one of the most important endeavours in today's clinical investigation. Over more than 30 years of research, no disease-modifying treatment has been approved by either the FDA or the EMA to treat Alzheimer's disease. Recently, the evidence of pathological alterations in the brain tissue has been gathered showing that the signs of brain damage appear more than 20 years before the onset of Alzheimer's dementia. The major aim of this review is to underpin the idea that in Alzheimer's therapeutics, only prevention makes sense. It is difficult to visualise that would-be patients may be treated with endovenous administration of antibodies for several years to d…

0301 basic medicinemedicine.medical_specialtyClinical BiochemistryBrain damageDiseaseBiochemistryAsymptomaticAntioxidantsMice03 medical and health sciences0302 clinical medicineAlzheimer DiseaseAnimalsHumansVitamin EMedicineDementiaHealthy LifestyleTreatment FailureIntensive care medicinePathologicalNootropic AgentsAgedAged 80 and overClinical Trials as Topicbusiness.industryAntibodies MonoclonalCognitionGeneral MedicineMiddle Agedmedicine.diseaseClinical trialDisease Models Animal030104 developmental biologymedicine.symptombusiness030217 neurology & neurosurgeryMinimal cognitive impairmentEuropean Journal of Clinical Investigation
researchProduct

Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting

2019

We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health c…

0301 basic medicinemedicine.medical_specialtyCognitiveGenital Neoplasms FemaleInternational Cooperation[SDV.CAN]Life Sciences [q-bio]/CancerCancer Chemotherapy Cognitive Gynecologic Offspring Pregnancy[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics03 medical and health sciencesGenital Neoplasms Female/therapyGynecologicOffspring0302 clinical medicineSDG 3 - Good Health and Well-beingPregnancyHealth caremedicinePrenatal Exposure Delayed Effects/etiologyHumansChemotherapyRadiation treatment planningIntensive care medicineSocieties MedicalCancerPregnancy Complications Neoplastic/therapyPregnancyVaginal deliverybusiness.industryCancerHematologymedicine.diseasePrognosis3. Good healthCancer registryLong-term care030104 developmental biologyOncology030220 oncology & carcinogenesisPrenatal Exposure Delayed EffectsPractice Guidelines as TopicFemalePractice Guidelines as Topic/standardsbusinessBreast feedingPregnancy Complications Neoplastic
researchProduct

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

2021

Background & Aims A number of double, triple, and quadruple therapies have been proposed as first-line empiric treatments for Helicobacter pylori infection. However, knowledge of their worldwide and regional comparative efficacy is lacking. We examined the comparative effectiveness of all empirically used first-line regimens tested against standard triple treatment using a network meta-analysis of published randomized controlled trials. Methods Data extracted from eligible randomized controlled trials were entered into a Bayesian network meta-analysis to investigate the comparative efficacy of H pylori infection empiric first-line regimens and to explore their effectiveness rank order. The …

0301 basic medicinemedicine.medical_specialtyComparative Effectiveness ResearchTime FactorsEfficacyVonoprazanSettore MED/12 - GASTROENTEROLOGIANetwork Meta-Analysislaw.inventionHelicobacter Infections03 medical and health sciences0302 clinical medicineRandomized controlled trialDrug TherapyLevofloxacinlawInternal medicinemedicineHumansFirst-Line RegimensRandomized Controlled Trials as TopicHepatologybiologyHelicobacter pyloribusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyBayes TheoremProton Pump InhibitorsOdds ratioHelicobacter pyloribiology.organism_classificationConfidence intervalAnti-Bacterial AgentsTreatmentRegimen030104 developmental biologyTreatment OutcomeMeta-analysisCombination030211 gastroenterology & hepatologyDrug Therapy Combinationbusinessmedicine.drug
researchProduct

Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project.

2015

BACKGROUND There is still uncertainty about what constitutes the best therapeutic practice in ulcerative colitis (UC). OBJECTIVE The purpose of the "UC Horizons Project" was to raise a series of questions regarding the management of UC to provide responses based on the best scientific evidence available. METHODS The 11 members of the scientific committee prepared draft answers to the 10 questions from available evidence after a literature search. A total of 48 Spanish gastroenterology specialists nationwide participated in the project. The national meeting discussed the 10 issues in working groups and reached consensus regarding the recommendations by anonymous, interactive vote following t…

0301 basic medicinemedicine.medical_specialtyConsensusAttitude of Health PersonnelAlternative medicineDelphi methodGastroenterologyScientific evidence03 medical and health sciences0302 clinical medicineInternal medicinePhysiciansSurveys and QuestionnairesmedicineImmunology and AllergyHumansDisease management (health)Thiopurine methyltransferasebiologybusiness.industryRemission InductionGastroenterologyDisease ManagementEvidence-based medicineDiscontinuation030104 developmental biologyFamily medicinePractice Guidelines as Topicbiology.protein030211 gastroenterology & hepatologyColitis UlcerativeWorking groupbusinessInflammatory bowel diseases
researchProduct